The Enterprise Value as of December 2025 (TTM) for Xilio Therapeutics, Inc. (XLO) is -57598257.00

According to Xilio Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -57598257.00. This represents a change of 540.84% compared to the average of -8987961.40 of the last 4 quarters.

Xilio Therapeutics, Inc. (XLO) Historical Enterprise Value (quarterly & annually)

How has XLO Enterprise Value performed in the past?

The mean historical Enterprise Value of Xilio Therapeutics, Inc. over the last ten years is 837.60M. The current -57598257.00 Enterprise Value has changed -787.66% with respect to the historical average. Over the past ten years (40 quarters), XLO's Enterprise Value was at its highest in in the December 2020 quarter at 428.64M. The Enterprise Value was at its lowest in in the June 2022 quarter at -59197927.12.

Xilio Therapeutics, Inc. (XLO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Xilio Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xilio Therapeutics, Inc. (XLO) Average Enterprise Value

How has XLO Enterprise Value performed in the past?

The current Enterprise Value of Xilio Therapeutics, Inc. (XLO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xilio Therapeutics, Inc. (XLO) Enterprise Value vs. Peers

How is XLO’s Enterprise Value compared to its peers?

Xilio Therapeutics, Inc.’s Enterprise Value is greater than PDS Biotechnology Corporation (-26077209422.00), less than Actinium Pharmaceuticals, Inc. (-7013958.00), less than Tempest Therapeutics, Inc. (9.57M), less than OnKure Therapeutics, Inc. (-34012234.00), less than LAVA Therapeutics N.V. (19.39M), less than Kezar Life Sciences, Inc. (20.85M), less than FibroGen, Inc. (103.14M), less than Skye Bioscience, Inc. (15.30M), less than Tvardi Therapeutics, Inc. (18.02M), less than Aligos Therapeutics, Inc. (26.21M),

Build a custom stock screener for Xilio Therapeutics, Inc. (XLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xilio Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xilio Therapeutics, Inc. (XLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xilio Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.